Phase I study of Vinorelbine(VNR) and S-1 combination therapy for the elderly patients with advanced non-small-cell lung cancer.
Phase 1
- Conditions
- advanced non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000026093
- Lead Sponsor
- Tokyo Metropolitan Tama Medical Center Department of respiratory medicine and clinical oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
1) Symptomatic brain metastasis 2) Severe infection 3) Severe comorbidity (heart failure Tendency to hemorrhages uncontrollable hypertension, uncontrollable diabetes, etc) 4)Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 5) Planning of surgery or thoracic radiotherapy during the trial. 6) With a history of drug sensitivity for S-1 or Vinorelbine. 7) Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recommended dose of S-1 and VNR combination therapy.
- Secondary Outcome Measures
Name Time Method We evaluate the efficacy and safety of S-1 and VNR combination therapy for the elderly patients with advanced non-small-cell lung cancer.